Journal Mobile Options
Table of Contents
Vol. 77, No. 1, 2008
Issue release date: December 2007
Psychother Psychosom 2008;77:12–16
(DOI:10.1159/000110055)

Duloxetine Does Not Relieve Painful Physical Symptoms in Depression: A Meta-Analysis

Spielmans G.I.
Department of Psychology, Metropolitan State University, Saint Paul, Minn., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background:Duloxetine inhibits both serotonin and norepinephrine reuptake and is marketed as a treatment for both the core emotional symptoms and painful physical complaints that often accompany depression. Some studies have found that duloxetine is efficacious in treating painful symptoms associated with depression but these findings have been inconsistent. Several narrative review articles have reached positive conclusions about the efficacy of duloxetine as an analgesic in depression but there has been no quantitative systematic review regarding the impact of duloxetine on pain among this population. A meta-analysis of data pertaining to duloxetine’s purported analgesic effects on depressed patients was thus undertaken. Methods:Studies were selected through searching Medline and Cochrane Trial databases as well as examining Lilly’s public clinical trial database. A random effects model was used. Results: Across five trials, the results indicate a very small (d = 0.115) and statistically nonsignificant (p = 0.057) analgesic effect for duloxetine. Additionally, some of the relevant data on duloxetine’s effects have not been reported fully, making it likely that the obtained results reflect an overestimate of its true impact on painful physical symptoms in depression. Discussion:The current analysis is based on a small number of studies; further trials may yield significant results favoring duloxetine. Based upon the currently available evidence, the marketing of duloxetine as an antidepressant with analgesic properties for people with depression does not appear to be adequately supported.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Perahia DGS, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ: Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367–378.
  2. Detke MH, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457–470.
  3. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43–53.
  4. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Erlbaum, 1988.
  5. Study 6553. Duloxetine Once-Daily Dosing versus Placebo in Patients with Major Depression and Pain. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_6353.pdf
  6. Study 4689b. Duloxetine Once-Daily Dosing versus Placebo in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4689b.pdf
  7. Study 4689a. Duloxetine Once-Daily Dosing versus Placebo in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4689a.pdf
  8. Study 4091b. Duloxetine versus Placebo and Paroxetine in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4091b.pdf
  9. Study 4091a. Duloxetine versus Placebo and Paroxetine in the Acute Treatment of Major Depression. http://lillytrials.com/results_files/cymbalta/cymbalta_summary_4091a.pdf
  10. Hedges LV: Statistical considerations; in Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, Russell Sage, 1994, pp 29–38.
  11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analysis. BMJ 2003;327:557–560.
  12. Hedges LV, Pigott TD: The power of statistical tests in meta-analysis. Psychol Methods 2001;6:203–217.
  13. Hardy RJ, Thompson SG: Detecting and describing heterogeneity in meta- analysis. Stat Med 1998;17:841–856.
  14. Wampold BE, Mondin G, Moody M, Stich F, Ahn H: A meta-analysis of outcome studies comparing bona fide psychotherapies: empirically, ‘All must have prizes.’ Psych Bull 1997;122:203–215.
  15. Gleser LJ, Olkin I: Stochastically dependent effect sizes; in Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, Russell Sage, 1994, pp 339–356.
  16. Comprehensive Meta-Analysis (version 2.2.03). Englewood, Biostat, 2006.
  17. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. San Diego, Academic Press, 1985.
  18. Muñoz RA, McBride ME, Brnabic AJM, Lopez CJ, Hetem LAB, Secin R, Dueñas HJ: Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 2005;86:93–98.
  19. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS: Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309–318.
  20. Clark P, Lavielle P, Martinez H: Learning from pain scales: patient perspective. J Rheumatol 2003;30:1584–1588.
  21. www.lillytrials.com
  22. http://lillytrials.com/docs/ctr_policy.pdf
  23. Moore D, Zimm A: Eli Lilly net rises as Cymbalta sales almost double (update 5). http://www.bloomberg.com/apps/news?pid =newsarchive&sid=aN6ts3UJxl2Y
  24. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17–28.
  25. http://www.depressionhurts.com/stories/stories.jsp?reqNavId=3
  26. http://www.depressionhurts.com/options/options.jsp
  27. www.depressionhurts.com
  28. Schatzberg AF: Efficacy and tolerability of duloxetine, a novel dual reptake inhibitor in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(suppl 13):30–37.

    External Resources

  29. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;26:106–132.
  30. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003;5:19–28.
  31. Stewart DE: Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry 2003;64(suppl 7):12–16.

    External Resources

  32. Lynch ME: Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30–36.
  33. Cowen PJ, Oglivie AD, Gama J: Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 2005;21:345–355.
  34. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K: Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17–22.
  35. Von Korff M, Simon G: The relationship between pain and depression. Br J Psychiatry 1996;30(suppl):101–108.
  36. Ohayon MM, Schatzberg AF: Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39–47.
  37. Trivedi MH: Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 2006;67(suppl 6):27–32.

    External Resources

  38. Henningsen P, Lowe B: Depression, pain, and somatoform disorders. Curr Opin Psychiatry 2006;19:19–24.
  39. Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R: The association of depression and painful physical symptoms – a review of the European literature. Eur Psychiatry 2006;21:379–388.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50